Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pemigatinib versus chemotherapy in unresectable or metastatic cholangiocarcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 3 | Status: TERMINATED